Evidence map›Paper›PMID 33326051›Full record

ArticleBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2021

[How to assess the elimination of viral hepatitis B, C, and D in Germany? Outcomes of an interdisciplinary workshop].

Ruth Zimmermann, Wiebe Külper-Schiek, Gyde Steffen, Sofie Gillesberg Lassen, Viviane Bremer, Sandra Dudareva, die Hepatitis-Monitoring-Arbeitsgruppe

Open access · hybridAbstract read
In one paragraph

Article in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Aspects that facilitate access to care for viral hepatitis: An evaluative research.Sao Paulo medical journal = Revista paulista de medicina · 2024
    Article
  2. [HIV/HCV Among Drug Users in Germany: Elimination Targets in the Mirror of Practice].Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ruth ZimmermannAbteilung für Infektionsepidemiologie, Fachgebiet 34 HIV/AIDS und andere sexuell oder durch Blut übertragene Infektionen, Robert Koch-Institut, Seestr. 10, 13353, Berlin, Deutschland. ZimmermannR@rki.de.
Wiebe Külper-SchiekAbteilung für Infektionsepidemiologie, Fachgebiet 34 HIV/AIDS und andere sexuell oder durch Blut übertragene Infektionen, Robert Koch-Institut, Seestr. 10, 13353, Berlin, Deutschland.
Gyde SteffenAbteilung für Infektionsepidemiologie, Fachgebiet 34 HIV/AIDS und andere sexuell oder durch Blut übertragene Infektionen, Robert Koch-Institut, Seestr. 10, 13353, Berlin, Deutschland.
Sofie Gillesberg LassenAbteilung für Infektionsepidemiologie, Fachgebiet 34 HIV/AIDS und andere sexuell oder durch Blut übertragene Infektionen, Robert Koch-Institut, Seestr. 10, 13353, Berlin, Deutschland.
Viviane BremerAbteilung für Infektionsepidemiologie, Fachgebiet 34 HIV/AIDS und andere sexuell oder durch Blut übertragene Infektionen, Robert Koch-Institut, Seestr. 10, 13353, Berlin, Deutschland.
Sandra DudarevaAbteilung für Infektionsepidemiologie, Fachgebiet 34 HIV/AIDS und andere sexuell oder durch Blut übertragene Infektionen, Robert Koch-Institut, Seestr. 10, 13353, Berlin, Deutschland.
die Hepatitis-Monitoring-Arbeitsgruppe
Robert Koch Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2016, the World Health Organization (WHO) released a strategy to eliminate hepatitis B, C, and D and defined indicators to monitor the progress. The Robert Koch Institute organized an interdisciplinary working meeting in 2019 to identify data sources and gaps.

objectivesThe objectives were to network, to create an overview of the data sources available in Germany on hepatitis B and C, and to discuss how to construct indicators. MATERIALS AND

methodsWe extracted the WHO indicators relevant for Germany and determined how they can be constructed on the basis of available data. Stakeholders from public health services, clinics, laboratories, health insurance companies, research institutes, data holders, and registries attended a workshop and discussed methods of constructing the indicators for which data are lacking. Data sources and data were evaluated and prioritized with regard to their quality and completeness.

resultsIndicators on prevalence, incidence, prevention, testing and diagnosis, treatment, cure, burden of sequelae, and mortality for the general population can be constructed using secondary data such as diagnosis, health service, and registry data, data from laboratories and hospitals as well as population-based studies. Data sources for vulnerable groups are limited to studies among drug users, men who have sex with men, and about HIV coinfected patients. Data for migrants, prisoners, and sex workers are largely lacking as well as data on burden of disease from chronic viral hepatitis in the general population.

conclusionsWe identified data sources, their limitations, and methods for construction for all selected indicators. The next step is to convert the ideas developed into concrete projects with individual stakeholders.

Indexed as

Hepatitis BHepatitis CHepatitis, Viral, HumanSexual and Gender MinoritiesGermanyHomosexuality, MaleHumansMaleData sourcesEpidemiologyGeneral populationIndicatorsSecondary dataVulnerable groups

Identifiers

PMID33326051
PMCPMC7772161
OpenAlexW3113179809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.